Bulk Pharmaceutical API Sources for OCUSERT PILO-20

Bulk Pharmaceutical API Sources for OCUSERT PILO-20

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-512-506
TimTec		ST069319
TimTec		SBB012409

Bulk Active Pharmaceutical Ingredient (API) Sources for OCUSERT PILO-20

Last updated: August 2, 2025

Introduction

The pharmaceutical industry continuously evolves, emphasizing the importance of high-quality active pharmaceutical ingredients (APIs) in delivering therapeutic efficacy and meeting regulatory standards. OCUSERT PILO-20, a notable controlled-release formulation containing levodopa and carbidopa, addresses Parkinson's disease treatment through a unique delivery system. For manufacturers and stakeholders, sourcing reliable bulk APIs is crucial for ensuring product integrity, regulatory compliance, and competitive advantage. This analysis explores the pipeline of API sources relevant to OCUSERT PILO-20, focusing on trends, key suppliers, regulatory considerations, and strategic procurement insights.

Overview of OCUSERT PILO-20 and API Components

OCUSERT PILO-20's formulation primarily comprises levodopa (L-DOPA) and carbidopa, combined within a controlled-release delivery system. Levodopa remains the cornerstone of Parkinson's therapy, necessitating consistent supply chains with high purity standards. Carbidopa enhances levodopa's bioavailability by inhibiting peripheral conversion, making its sourcing equally critical.

The APIs used in OCUSERT PILO-20 must adhere to stringent quality standards, including Good Manufacturing Practice (GMP) compliance, batch consistency, and impurity profiling, verified through comprehensive analytical testing.

Key API Sources for Levodopa and Carbidopa

Global Manufacturing Landscape

The procurement of APIs such as levodopa and carbidopa involves navigating a global network of suppliers, encompassing established multinational pharmaceutical API producers, Contract Manufacturing Organizations (CMOs), and emerging regional players. The choice of source hinges on factors like regulatory compliance, cost, quality assurance, production capacity, and geopolitical stability.

Major API Suppliers for Levodopa

1. Shanghai Sine Pharmaceutical Co., Ltd. (China)
   Recognized for robust GMP-compliant production of dopaminergic APIs, Shanghai Sine supplies pharmaceutical-grade levodopa used in various formulations. Their APIs meet USFDA and EMA standards, making them suitable for controlled-release systems like OCUSERT PILO-20.

2. Zhejiang Heben Pharmaceuticals (China)
   This manufacturer produces high-purity levodopa with a focus on consistency and advanced purification techniques. Their offerings are verified through rigorous analytical testing and fulfill international pharmacopoeia standards.

3. Ferraroni (Italy)
   An established European supplier specializing in dopaminergic API synthesis. Ferraroni emphasizes quality, with ISO certifications and extensive experience catering to pharmaceutical formulators producing sustained-release delivery systems.

4. Jiangsu Hengrui Medicine Co., Ltd. (China)
   A leading innovator with GMP-certified API production, Jiangsu Hengrui offers levodopa with assured purity profiles suitable for complex formulations, including controlled-release systems.

5. Akorn, Inc. (USA)
   As a noted supplier in North America, Akorn provides GMP-compliant APIs, including levodopa, supporting distribution within regulatory markets such as the US.

Major API Suppliers for Carbidopa

1. Zhejiang Huahai Pharmaceutical Co., Ltd. (China)
   Known for high-quality synthesis of carbidopa, with proven regulatory track records and GMP certifications suitable for licensed pharmaceutical products.

2. Cipla Ltd. (India)
   Cipla manufactures and exports pharmaceutical-grade carbidopa, emphasizing compliance with international standards and offering reliable supply for branded and generic formulations.

3. Sinemet Manufacturing Inc. (USA)
   A division specializing in high-purity APIs, providing carbidopa with rigorous quality assurance processes to ensure batch uniformity.

4. Granules India (India)
   An emerging supplier with scalable manufacturing for GMP-compliant carbidopa, with bearings on cost-efficiency and global regulatory adherence.

5. Keur Pharma (Egypt)
   A regional supplier with a focus on quality assurance, comprehensive testing, and GMP standards, facilitating regional distribution.

API Quality and Regulatory Standards

For APIs used in OCUSERT PILO-20, compliance with regulatory standards—such as USP, EP, or JP—is non-negotiable. Suppliers must demonstrate adherence to current Good Manufacturing Practices (cGMP) and conduct rigorous stability and impurity testing. Additionally, validation of synthetic pathways, thorough impurity profiling, and validated analytical methods are essential to ensure batch-to-batch consistency.

International regulatory agencies like the FDA and EMA scrutinize API manufacturing facilities, emphasizing documentation, quality control processes, and supply chain transparency. Consequently, sourcing from accredited suppliers with established GMP certifications guarantees smoother approval processes and minimized regulatory risks.

Emerging Trends in API Sourcing for Controlled-Release Formulations

1. Regional Diversification: Increasing emphasis on regional API manufacturing to mitigate supply chain disruptions, especially driven by geopolitical factors and recent global events.

2. Synthetic Innovation: Development of synthetic pathways that reduce impurities and enhance yield, leading to higher API purity which is vital in complex delivery systems.

3. Digital Traceability: Adoption of blockchain and supply chain digitization to enhance transparency, verify authenticity, and ensure traceability throughout the API lifecycle.

4. Sustainable Practices: Emphasis on green chemistry and environmentally sustainable manufacturing practices, aligning with global regulatory and corporate ESG standards.

Strategic Sourcing Considerations

For stakeholders involved in OCUSERT PILO-20 production:

• Regulatory Compliance: Prioritize suppliers with proven GMP compliance, existing regulatory approvals, and transparent documentation.

• Quality Assurance: Enforce rigorous qualification and validation protocols, including audit rights and analytical testing before acceptance.

• Supply Security: Diversify sources to mitigate risks of shortages, geopolitical disruptions, or manufacturing delays.

• Cost Management: Balance the premium of established suppliers against emerging regional manufacturers offering competitive pricing with comparable standards.

• Lifecycle Management: Engage with suppliers capable of scale-up, process validation, and continuous improvement to accommodate evolving product demands.

Conclusion

The successful production of OCUSERT PILO-20 hinges on sourcing high-quality, GMP-compliant APIs—particularly levodopa and carbidopa—from reputable global manufacturers. Ensuring supply chain stability, regulatory adherence, and product consistency aligns with industry best practices and strategic objectives. As the pharmaceutical landscape shifts, integrating emerging trends such as regional manufacturing, digital traceability, and sustainable practices will be paramount for stakeholders committed to delivering efficacious Parkinson’s treatments.

---

Key Takeaways

• Reputable international suppliers such as Shanghai Sine, Zhejiang Heben, and Jiangsu Hengrui offer high-purity levodopa suited for controlled-release formulations like OCUSERT PILO-20.
• Carbidopa sourcing from suppliers like Zhejiang Huahai and Cipla ensures regulatory compliance and high batch consistency.
• Supplier qualification processes, including GMP certification and analytical validation, are critical to ensure API quality.
• Diversification of API sources mitigates supply chain risks amid geopolitical and logistical challenges.
• Embracing emerging trends—such as green chemistry, digital traceability, and regional manufacturing—can enhance supply security and compliance.

---

FAQs

1. What are the primary considerations when sourcing APIs for controlled-release formulations such as OCUSERT PILO-20?
Ensuring API purity, GMP compliance, chemical stability, and consistent supply are essential. Suppliers must meet regulatory standards (USP, EP, JP) and provide thorough analytical data to confirm quality.

2. Are regional API manufacturers reliable for sourcing APIs like levodopa and carbidopa?
Yes. Many regional manufacturers in Asia, India, and the Middle East have made significant advances in GMP compliance and quality assurance. Qualification and audit processes are vital to verifying reliability.

3. How do regulatory standards impact API sourcing decisions?
APIs must meet international standards (USP, EP, JP) and origin from GMP-certified facilities. Regulatory oversight influences supplier selection, documentation requirements, and batch validation processes.

4. What role does API customization or synthetic innovation play in current sourcing strategies?
Custom synthesis pathways that improve purity and reduce impurities are increasingly valued. Synthetic innovations enhance batch consistency, crucial for complex delivery systems like OCUSERT.

5. How is supply chain resilience maintained amid disruptions?
Stakeholders diversify suppliers across regions, develop long-term contracts, and maintain safety stock. Embracing digital traceability and establishing relationships with multiple accredited sources are vital for resilience.

---

Sources:

1. [1] United States Pharmacopeia (USP): General Chapter <791> Levodopa.
2. [2] European Pharmacopoeia (EP): Monograph on Levodopa.
3. [3] Global Industry Analysts Report: API Market Overview.
4. [4] U.S. Food and Drug Administration (FDA): Guidance for Industry - Pharmaceutical Quality System.
5. [5] World Health Organization (WHO): International Standards for APIs.